Medical/Pharmaceuticals
Volition Achieves CE Mark for Nu.Q® NETs Test
to aid the detection and evaluation of diseases associated with NETosis AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® NETs test has been CE marked for the detection and evaluat...
2022-05-31 20:00
2893
I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency
SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the completion of patient enrollment in a Phase 3 clinica...
2022-05-31 20:00
1482
GBM AGILE OPENS TO PAXALISIB IN EUROPE
SYDNEY, May 31, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the GBM AGILE study in glioblastoma (NCT03970447) has opened recruitment to the paxalisib arm inEurope. University Hospital Zurich...
2022-05-31 19:20
3042
Illuccix® Granted Transitional Pass-Through Payment Status
INDIANAPOLIS, May 31, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced that its prostate cancer imaging agent Illuccix® (kit for preparation of gallium Ga 68 gozetotide injection) has been granted Transitional Pass-Through Payment Status by the U.S...
2022-05-31 19:00
1148
ETNA™ DEVICE FROM THE LEADING DIGITAL HEALTH & AI COMPANY INNODEM NEUROSCIENCES RECEIVES FDA "BREAKTHROUGH" DESIGNATION FOR MULTIPLE SCLEROSIS
MONTREAL, May 31, 2022 /PRNewswire/ -- Innodem Neurosciences, a leading provider of innovation and technology for the convergence of neurosciences, digital health, pharmaceutical and artificial intelligence, is proud to announce that its novel mobile eye tracking technology for people living with...
2022-05-31 18:00
1410
Latest Results from AENEAS Study of Hansoh Pharma's Ameile® Published in Top International Academic Journal JCO
SHANGHAI, May 31, 2022 /PRNewswire/ -- Recently, the Journal of Clinical Oncology (JCO, IF:44.544), an internationally renowned oncology journal, published an online paper on the AENEAS study of Ameile® (Aumolertinib Mesylate Tablets, an innovative drug developed by Hansoh Pharma), which was led ...
2022-05-31 17:56
619
AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease
SHANGHAI, May 30, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, announces that the first patient has been dosed in its US Phase 1 st...
2022-05-31 11:30
1375
Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists
Preclinical Studies on the Potential Application of Transcenta's First-In-Class Gremlin1 Targeting Antibody in the Treatment of Androgen Receptor-Negative/Low Prostate Cancer SUZHOU, China, May 30, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage bio...
2022-05-31 08:08
1208
Medical training in Vietnam impressively attracts international students.
HO CHI MINH CITY, Vietnam, May 30, 2022 /PRNewswire/ -- In the last few days of May, many colleagues fromIndia, Honduras, Nigeria, etc., came to Vietnam to be admitted to the Medical Major of Hong BangInternational University (HIU). This is a significant milestone for the Vietnamese board of educ...
2022-05-30 20:08
2895
The Global Fight Against Monkeypox: Zelixir Biotech Predicts Monkeypox Protein Structures
Abstract: China's biotech company Zelixir Biotech publishes 600+ protein structure predictions for the Monkeypox proteome SHANGHAI, May 30, 2022 /PRNewswire/ -- Zelixir Biotech announces it has predicted more than 600 structures and added functional annotations of proteins from monkeypox virus p...
2022-05-30 18:36
1782
Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
GAITHERSBURG, Md. and SUZHOU, China, May 30, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the launch of a Phase I clinical trial of the Company's si...
2022-05-30 16:40
2105
Experts attending P&G Health's Global Webinar Series highlight underdiagnosis concerns as Peripheral Neuropathy becomes more prevalent
- Often underestimated and diagnosed late, increasing awareness and early-stage screening of Peripheral Neuropathy by primary care physicians can help prevent long-term complications and quality of life restrictions. - The Global Webinar Series for healthcare professionals has 'Virtual Pavilions...
2022-05-30 16:12
2252
RhoVac's phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint
STOCKHOLM, May 30, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, regrets to announce today onMay 29th, 2022, that its phase IIb study in prostate cancer, BRaVac, in spite of the previous positive results related to the compound, failed to demonstrate RV001 (on...
2022-05-30 11:04
1622
United BioPharma Receives TFDA Approval for Phase 2 IND for UB-221 to Treat Chronic Spontaneous Urticaria
TAIPEI, May 30, 2022 /PRNewswire/ -- Taiwan-based United BioPharma (UBP) has
announced the approval of a Phase 2 clinical trial with novel anti-IgE
monoclonal antibody UB-221 by the Taiwan Food and Drug Administration (TFDA).
2022-05-30 10:59
1653
InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients with platinum-resistant recurrent ovarian cancer
NANJING, China, May 29, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label...
2022-05-30 08:10
1648
Illuccix® Reimbursement Milestone and Launch Updates: Pass-Through Status Granted in the U.S.
MELBOURNE, Australia and INDIANAPOLIS, May 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium (68...
2022-05-30 08:02
2571
MedAlliance's SELUTION SLR drug-eluting balloon (DEB) receives FDA investigational device exemption (IDE) approval, making it the first limus DEB to be available to US patients
GENEVA, May 30, 2022 /PRNewswire/ -- The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent (DES). SELUTION SLR was also the first DEB (Drug Eluting Balloon) granted "breakthrough device de...
2022-05-30 08:00
2081
IASO Biotherapeutics' Equecabtagene Autoleucel, the World's First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA
SAN JOSE, Calif., NANJING, China and SHANGHAI, May 28, 2022 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, announced today thatChina's National Medic...
2022-05-28 19:33
4956
Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting
BEIJING, SHANGHAI and BOSTON, May 27, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) is pleased to announce that the phase I clinical data of KRAS G12C inhibitor JAB-21822 will be presented in the form of poster at the upcoming 2022 annual meeting of American Society of Clinical Oncology (ASCO) fr...
2022-05-28 00:22
5971
Asieris to present a study protocol of APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy（NAC）for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting
SHANGHAI, May 27, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other major diseases announced that ANTICIPATE Study will be presented at the...
2022-05-27 22:16
2770
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 321 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 299 media titles]
2024-04-15 17:33
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 288 media titles]
2024-04-12 15:14
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
[Picked up by 275 media titles]
2024-04-15 08:00
LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
[Picked up by 274 media titles]
2024-04-11 11:00
Most Read
LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
2024-04-11 11:00
6653
XCMG Machinery Launches Premium G2 Crane Brand
2024-04-12 14:39
5728
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
2024-04-12 15:14
5224
